New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
ApexOnco Front Page
Recent articles
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.